Bain buys Mitsubishi pharma unit; Bausch + Lomb deal talks come up empty
BioPharma Dive
by BioPharma Dive staff
3d ago
The investment firm is acquiring Mitsubishi Tanabe Pharma in a deal valued at $3.3 billion. Elsewhere, Bausch + Lomb hasn’t yet found a suitor and a pair of biotechs cut staff ..read more
Visit website
Immune drugmakers Alumis and Acelyrin to merge
BioPharma Dive
by Gwendolyn Wu
3d ago
The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the new company with a bigger cash balance and three drugs in testing ..read more
Visit website
Vertex challenger Sionna prices $191M IPO
BioPharma Dive
by Gwendolyn Wu
3d ago
The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or be used in new, multi-drug combinations ..read more
Visit website
Bristol Myers, bracing for key patent losses, deepens cost-cutting plan
BioPharma Dive
by Delilah Alvarado
3d ago
The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies across multiple areas of the business,” its CFO told analysts on a conference call.  ..read more
Visit website
Eli Lilly’s earnings, shares lifted by obesity drug sales
BioPharma Dive
by Kristin Jensen
4d ago
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for its weight loss medicines in January ..read more
Visit website
Bristol Myers gives first peek at closely watched launch of schizophrenia drug
BioPharma Dive
by Jacob Bell
4d ago
Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the fourth quarter and is around 1,000 prescriptions weekly by late January ..read more
Visit website
Pfizer taps former Novartis exec to lead cancer drug push
BioPharma Dive
by Ben Fidler
4d ago
The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow sales in the years ahead.  ..read more
Visit website
GSK, Pfizer sales of RSV shots slow as vaccination rates ebb
BioPharma Dive
by Delilah Alvarado
4d ago
Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use ..read more
Visit website
Novo outlines new late-stage study of obesity drug CagriSema
BioPharma Dive
by Jonathan Gardner
4d ago
CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer duration in the new trial ..read more
Visit website
Amgen obesity drug on hold; Regeneron sets first dividend
BioPharma Dive
by Ned Pagliarulo
4d ago
The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million ..read more
Visit website

Follow BioPharma Dive on FeedSpot

Continue with Google
Continue with Apple
OR